Revium Rx. (RVRC): Total Liabilities
$1.42M
As of 2025-12-31
$1.59M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.42M | +145.7% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $576.0K | n/a | 2026-03-31, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Revium Rx. (RVRC) | 2025-12-31 | $1.42M | +145.7% |
| Lunai Bioworks Inc. (LNAI) | 2025-06-30 | $29.58M | -5.0% |
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | $968.0K | +8.2% |
| GT Biopharma, Inc. (GTBP) | 2025-09-30 | $1.32M | n/a |
| CNS Pharmaceuticals, Inc. (CNSP) | 2025-12-31 | $4.10M | +62.5% |
| GRI Bio, Inc. (GRI) | 2025-12-31 | $2.66M | +55.7% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $2.42M | -6.4% |
| Dermata Therapeutics, Inc. (DRMA) | 2025-12-31 | $1.64M | -16.8% |
| Processa Pharmaceuticals, Inc. (PCSA) | 2025-12-31 | $2.24M | +45.9% |
Compare RVRC, LNAI, XBIO, GTBP side by side · Screen every company in Pharmaceutical Preparations ↗